Submission deadline: October 20, 2025 (23:59 GMT)

12 October 2025

Kigali, Rwanda and Cape Town, South Africa -- Are you an early or mid-career researcher with bold ideas to transform cancer care in Africa?

AORTIC and Bio Usawa have partnered to establish a brand new microgrant program in support of emergent innovation or health systems research that could lead to transformative solutions in oncology.

This is your opportunity to win a grant of up to USD 5,000, publish in the AORTIC Journal, and present your project at AORTIC events.

Scan QR code to apply:

About Bio Usawa Inc.

Bio Usawa is Rwanda's leading biotechnology company dedicated to democratizing access to life-saving biopharmaceuticals across Africa. Founded on the principle that geographic location should not determine healthcare outcomes, the company specializes in developing and manufacturing affordable, high-quality monoclonal antibodies targeting cancer, diabetes complications, infectious diseases, and autoimmune conditions. Bio Usawa's leadership team brings decades of experience from leading global biotech companies and international regulatory agencies.

About AORTIC:

AORTIC is an African non-governmental organization dedicated to cancer control research in Africa. Its mission is to improve cancer outcomes through research, education, and collaboration with national health ministries and global partners. AORTIC also plays an active role in training and uniting cancer professionals, with a focus on strengthening cancer care systems in African countries.

For more information, visit: www.aortic-africa.org